Sirna Therapeutics - About the company
Sirna Therapeutics is an acquired company based in San Francisco (United States), founded in 1992. It operates as a Develops RNAi-based therapies. Sirna Therapeutics has raised an undisclosed amount in funding. The company has 3116 active competitors, including 1087 funded and 780 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Nanopore Technologies.
Company Details
Sirna Therapeutics is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. The company develops small interfering RNA (siRNA) drugs. The company started a clinical trial of its siRNA-based treatment for age-related macular degeneration. The company went public in 2008. Sirna Therapeutics is a biotechnology company exploring the use of RNA interference in human disease therapy. The company was acquired by Merck & Co. in 2006 for $1.1B. In 2014, Sirna was acquired by Alnylam from Merck for $175M.
Key Metrics
Founded Year
1992
Location
San Francisco, United States
Stage
Acquired
Latest Funding Round
Ranked
1289th among 3116 active competitors
Employee Count
14 as on May 31, 2026
Exit Details
Acquired by Alnylam (Jan 12, 2014)
Legal entities associated with Sirna Therapeutics
Sirna Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
SIRNA THERAPEUTICS INC CIN: 341697351 , United States, Active | Dec 31, 1991 | - | - | - |
Sirna Therapeutics's acquisition details
Click here to take a look at Sirna Therapeutics's acquisition in detail
Sign up to download Sirna Therapeutics' company profile
Sirna Therapeutics's funding and investors
Sirna Therapeutics has raised funding over 3 rounds. Its first funding round was on Apr 24, 2003. Its latest funding round was a Post IPO round on Jul 07, 2005 for $*****. 3 investors participated in its latest round. Sirna Therapeutics has 6 institutional investors.
Here is the list of recent funding rounds of Sirna Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 07, 2005 | 9538611 | Post IPO | 9578113 | 1488003 | 8992769 | 9434188 |
May 2004 | 9708671 | Post IPO | 5468308 | 8033375 | 2712167 | 9417006 |
Apr 24, 2003 | 7436653 | Post IPO | 9916223 | 6085806 | 5399942 |
Access funding benchmarks and valuations. Sign up today!View details of Sirna Therapeutics's funding rounds and investors
Sirna Therapeutics' founders and board of directors
Founder? Claim ProfileSirna Therapeutics' employee count trend
Sirna Therapeutics has 14 employees as of May 26. Here is Sirna Therapeutics's employee count trend over the years:
Uncover Sirna Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Sirna Therapeutics's Competitors and alternates
Top competitors of Sirna Therapeutics include Jazz Pharmaceuticals, Alnylam and Nanopore Technologies. Here is the list of Top 10 competitors of Sirna Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd | Nanopore Technologies 2005, Oxford (United Kingdom), Public | Manufacturer of portable and benchtop devices for real-time DNA sequencing | $1.26B | 75/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
5th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
7th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
8th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
9th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
1289th | Sirna Therapeutics 1992, San Francisco (United States), Acquired | Develops RNAi-based therapies | - | 37/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Sirna Therapeutics's competitors? Click here to see the top ones
Sirna Therapeutics's Investments and acquisitions
Sirna Therapeutics has made no investments or acquisitions yet.
Reports related to Sirna Therapeutics
Here is the latest report on Sirna Therapeutics's sector:
Are you a Founder ?
FAQs about Sirna Therapeutics
Explore our recently published companies
- Keith Wolfe Casting - Lumberton based, 1996 founded, Unfunded company
- Wood Things - Gretna based, 1996 founded, Unfunded company
- Lilian Jorgenson - Mclean based, 1996 founded, Unfunded company
- Tribology Solutions - Yaphank based, 1996 founded, Unfunded company
- First Fitness - Carrollton based, 1996 founded, Unfunded company
- East Texas Web Design - Lindale based, 1995 founded, Unfunded company
